Surgery vs. Chemoradiation for Esophageal Cancer
Part of Cancer, Digestive system clinical trials.
This trial compares surgery versus a strong combination of chemotherapy and radiation for people with esophageal squamous cell carcinoma that has been treated first with immunotherapy. It aims to find which approach leads to better outcomes after the initial immunotherapy and chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You are able to carry out daily activities with little or no help (ECOG 0–1).
- You have a type of esophageal cancer called squamous cell carcinoma that hasn't been treated yet.
- Your cancer is at a stage where surgery is possible (like stage II or III) and your doctors think all of the tumor can be removed.
- You have not had any other cancer in the last 5 years, and you do not have an active autoimmune disease or active hepatitis/HIV.
- Your heart and lungs are healthy enough for treatment, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving chemotherapy and radiation before surgery, followed by immunotherapy, can improve outcomes for people with a specific type of esophageal cancer that can be surgically removed.
This trial tests a new immunotherapy drug called toripalimab, given before, during, and after standard radiation and chemotherapy for esophageal cancer that hasn't spread. The goal is to see if adding this drug can improve outcomes for patients.
This trial tests giving a combination of chemotherapy, radiation therapy, and an immunotherapy drug before surgery for a type of esophageal cancer (squamous cell). The goal is to see if this approach helps shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
This study tests whether giving a combination of chemotherapy, radiation, and an immunotherapy drug (cadonilumab) before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a specific type of esophageal cancer that has not spread to other parts of the body.
This trial tests whether giving a combination of immunotherapy and chemotherapy before surgery can shrink esophageal cancer and improve outcomes. It is designed for patients with early-stage but treatable esophageal squamous cell carcinoma who are candidates for surgery.
This trial is testing different treatment combinations before surgery for people with locally advanced esophageal squamous cell carcinoma. The goal is to find which approach works best based on specific biomarkers like PD-L1 levels.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.